Abdel-qadir H, Tai F, Croxford R, et al. - In women developing heart failure (HF) associated with early breast cancer (EBC) chemotherapy, the characteristics and prognosis were studied and compared with cancer-free women who suffered HF due to other etiologies.

• A population-based retrospective cohort study of 804 women who received chemotherapy for EBC.

• Among participants, HF occurred after anthracyclines in 312, post-trastuzumab in 112, or after sequential therapy in 380.

• There were fewer comorbidities in women experiencing HF after cardiotoxic EBC chemotherapy vs cancer-free women with HF.

• A better prognosis was seen in trastuzumab-treated women who develop HF vs matched HF controls.

• Cardiovascular death at 5 years was 2.9% in the anthracycline-HF cohort (9.5% in controls) and 1.7% for females developing HF post-trastuzumab (4.3% for controls).